Hepion Pharmaceuticals (FRA:336) Change In Receivables : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals Change In Receivables?

Hepion Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was €0.00 Mil. It means Hepion Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Hepion Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Hepion Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Hepion Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hepion Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was €4.27 Mil.

Hepion Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Hepion Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Change In Receivables Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Hepion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Hepion Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Hepion Pharmaceuticals (FRA:336) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hepion Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Hepion Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Hepion Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	12.058	-	7.791	+	0.75 * 0	+	0.5 * 0
=	4.27

Hepion Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (FRA:336) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

HEPA:USA

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines